High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

Jens Kastrup; Julia S Johansen; Per Winkel; Jørgen Fischer Hansen; Per Hildebrandt; Gorm Boje Jensen; Christian M Jespersen; Erik Kjøller; Hans Jørn Kolmos; Inga Lind; Henrik Nielsen; Christian Gluud; CLARICOR Trial Group; Jens Kastrup; Julia S Johansen; Per Winkel; Jørgen Fischer Hansen; Per Hildebrandt; Gorm Boje Jensen; Christian M Jespersen; Erik Kjøller; Hans Jørn Kolmos; Inga Lind; Henrik Nielsen; Christian Gluud; null CLARICOR Trial Group

doi:10.1093/eurheartj/ehp049

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

Jens Kastrup, Julia S Johansen, Per Winkel, Jørgen Fischer Hansen, Per Hildebrandt, Gorm Boje Jensen, Christian M Jespersen, Erik Kjøller, Hans Jørn Kolmos, Inga Lind, Henrik Nielsen, Christian Gluud, CLARICOR Trial Group, Jens Kastrup, Julia S Johansen, Per Winkel, Jørgen Fischer Hansen, Per Hildebrandt, Gorm Boje Jensen, Christian M JespersenErik Kjøller, Hans Jørn Kolmos, Inga Lind, Henrik Nielsen, Christian Gluud, CLARICOR Trial Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

148 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-May

Originalsprog	Engelsk
Tidsskrift	European Heart Journal
Vol/bind	30
Udgave nummer	9
Sider (fra-til)	1066-72
Antal sider	6
ISSN	0195-668X
DOI	https://doi.org/10.1093/eurheartj/ehp049 https://doi.org/10.1093/eurheartj/ehp049
Status	Udgivet - 2009

Bibliografisk note

Keywords: Acute Coronary Syndrome; Aged; Biological Markers; Cause of Death; Coronary Angiography; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Lectins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prognosis; Survival Analysis

Adgang til dokumentet

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Kastrup, J., Johansen, J. S., Winkel, P., Hansen, J. F., Hildebrandt, P., Jensen, G. B., Jespersen, C. M., Kjøller, E., Kolmos, H. J., Lind, I., Nielsen, H., Gluud, C., CLARICOR Trial Group, Kastrup, J., Johansen, J. S., Winkel, P., Hansen, J. F., Hildebrandt, P., Jensen, G. B., ... CLARICOR Trial Group (2009). High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal, 30(9), 1066-72. https://doi.org/10.1093/eurheartj/ehp049, https://doi.org/10.1093/eurheartj/ehp049

Kastrup, J, Johansen, JS, Winkel, P, Hansen, JF, Hildebrandt, P, Jensen, GB, Jespersen, CM, Kjøller, E, Kolmos, HJ, Lind, I, Nielsen, H, Gluud, C, CLARICOR Trial Group, Kastrup, J, Johansen, JS, Winkel, P, Hansen, JF, Hildebrandt, P, Jensen, GB, Jespersen, CM, Kjøller, E, Kolmos, HJ, Lind, I, Nielsen, H, Gluud, C & CLARICOR Trial Group 2009, 'High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease', European Heart Journal, bind 30, nr. 9, s. 1066-72. https://doi.org/10.1093/eurheartj/ehp049, https://doi.org/10.1093/eurheartj/ehp049

@article{85cc3440708411de8bc9000ea68e967b,

title = "High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease",

abstract = "AIMS: Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). METHODS AND RESULTS: During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). CONCLUSION: High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.",

author = "Jens Kastrup and Johansen, {Julia S} and Per Winkel and Hansen, {J{\o}rgen Fischer} and Per Hildebrandt and Jensen, {Gorm Boje} and Jespersen, {Christian M} and Erik Kj{\o}ller and Kolmos, {Hans J{\o}rn} and Inga Lind and Henrik Nielsen and Christian Gluud and {CLARICOR Trial Group} and Jens Kastrup and Johansen, {Julia S} and Per Winkel and Hansen, {J{\o}rgen Fischer} and Per Hildebrandt and Jensen, {Gorm Boje} and Jespersen, {Christian M} and Erik Kj{\o}ller and Kolmos, {Hans J{\o}rn} and Inga Lind and Henrik Nielsen and Christian Gluud and {CLARICOR Trial Group}",

note = "Keywords: Acute Coronary Syndrome; Aged; Biological Markers; Cause of Death; Coronary Angiography; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Lectins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prognosis; Survival Analysis",

year = "2009",

doi = "10.1093/eurheartj/ehp049",

language = "English",

volume = "30",

pages = "1066--72",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

AU - Kastrup, Jens

AU - Johansen, Julia S

AU - Winkel, Per

AU - Hansen, Jørgen Fischer

AU - Hildebrandt, Per

AU - Jensen, Gorm Boje

AU - Jespersen, Christian M

AU - Kjøller, Erik

AU - Kolmos, Hans Jørn

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Gluud, Christian

AU - CLARICOR Trial Group

AU - Kastrup, Jens

AU - Johansen, Julia S

AU - Winkel, Per

AU - Hansen, Jørgen Fischer

AU - Hildebrandt, Per

AU - Jensen, Gorm Boje

AU - Jespersen, Christian M

AU - Kjøller, Erik

AU - Kolmos, Hans Jørn

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Gluud, Christian

AU - CLARICOR Trial Group, null

N1 - Keywords: Acute Coronary Syndrome; Aged; Biological Markers; Cause of Death; Coronary Angiography; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Lectins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prognosis; Survival Analysis

PY - 2009

Y1 - 2009

N2 - AIMS: Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). METHODS AND RESULTS: During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). CONCLUSION: High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.

AB - AIMS: Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). METHODS AND RESULTS: During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). CONCLUSION: High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.

U2 - 10.1093/eurheartj/ehp049

DO - 10.1093/eurheartj/ehp049

M3 - Journal article

C2 - 19270316

SN - 0195-668X

VL - 30

SP - 1066

EP - 1072

JO - European Heart Journal

JF - European Heart Journal

IS - 9

ER -